Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of DR30206 plus standard therapy in gastrointestinal tumors
CTR20251945Phase 2Active
- Sponsor
- Zhejiang Daer Biotechnology
- Start
- Jun 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of DR30206 in colorectal cancer (CRC), esophageal adenocarcinoma (EAC), gastric adenocarcinoma and 1 more, sponsored by Zhejiang Daer Biotechnology. Started Jun 2025; status: active.
02
Drugs
DR30206
03
Conditions
colorectal cancer (CRC)esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20251945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251945.